Key facts
- It has raised $2.7M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Impact Assets, One Mind, Catalytic Impact Foundation, Cedar Street Group, JLS Fund — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Ceretype
- ·The full record, as it builds
Funding rounds
No funding rounds for Ceretype are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ceretype
Developer of a brain imaging technology designed to revolutionize neuropsychiatric healthcare. The company's technology helps to improve drug discovery and patient care through its ability to subtype and classify the human brain on a neurobiological level and offers therapeutic strategies to address psychiatric illness and central nervous system disorders, enabling medical professionals to pioneer precision psychiatry.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 6
- Website
- ceretype.com/
- Ownership
- Privately Held (backing)
Ceretype doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ceretype shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ceretype in its N-PORT filings yet. We sweep new filings monthly.